Acutaas Chemicals
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Acutaas Chemicals is strategically transitioning towards high-margin specialty chemicals, particularly in battery and semiconductor sectors, which management believes will drive a projected 25% revenue growth in FY27. This pivot is supported by strong demand and long-term contracts, particularly in the CDMO space, which is expected to enhance margins despite current pressures from commodity segments. The company's disciplined capital allocation and focus on R&D are critical as it scales new facilities and navigates potential supply chain disruptions. While the macro environment remains cautiously optimistic, with improving domestic demand, risks such as regulatory changes and raw material price volatility could impact execution. Overall, Vista's forecast reflects confidence in Acutaas's ability to leverage its strategic initiatives for sustainable growth, with a target price of INR 4,194, indicating a 32% upside over the next 12 months
Why We Like This Stock
- Strong demand in battery and semiconductor chemicals supports revenue growth
- Management's disciplined approach to capital allocation and R&D investment enhances competitive positioning
- Long-term contracts in the CDMO space provide revenue visibility and margin stability
Things To Watch Out For
- Potential regulatory shifts and raw material price volatility pose execution risks
- Current margin pressures from commodity segments may impact overall profitability
- Execution challenges related to scaling new facilities could delay growth targets
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 717 | 1,007 | 1,339 | 1,500 | 1,820 |
| Profit Before Tax (Cr.) | 114 | 216 | 483 | 532 | 646 |
| PBT Margin | 15.9% | 21.4% | 36.1% | 35.4% | 35.5% |
| Net Profit (Cr.) | 72 | 167 | 365 | 403 | 490 |
| Earnings Per Share | 8.1 | 20.1 | 44.6 | 49.3 | 59.9 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| HDFC Securities | ▼ Sell | 2,210 | 21-Sep-2026 |
| Deven Choksey | ► Accumulate | 3,567 | 29-Jul-2026 |
| IDBI Capital | ▲ Buy | 4,001 | 27-Jul-2026 |
| Moneycontrol | ► Equalweight | nan | 06-Jul-2026 |
| Prabhudas Liladhar | ▲ Buy | 3,773 | 01-Jul-2026 |
| Kotak Securities | ▲ Buy | 2,980 | 04-May-2026 |
Company Overview
Show Company Profile
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients, as well as new chemical entities. It also provides specialty chemicals, including photoresist chemicals for semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.